Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis.

ABSTRACT:

Importance

Case reports of postoperative diabetic ketoacidosis in patients using sodium-glucose cotransporter 2 inhibitor (SGLT2i) medications underlie guidance by the US Food and Drug Administration to withhold SGLT2i medication for at least 3 days prior to surgery. Given the potential negative consequences associated with preoperative medication withholding, a large-scale evaluation of the risk of diabetic ketoacidosis in this population is needed.

Objective

To estimate the association between preoperative SGLT2i medication use and postoperative diabetic ketoacidosis in a population of patients who underwent a variety of emergency surgeries. Emergency surgery was chosen given the assumption that a patient would be unable to withhold their SGLT2i medication per the current

SUBMITTER: Dixit AA 

PROVIDER: S-EPMC11840685 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature